Heart transplantation is in high demand, however it is severely limited due to the short supply of donor organs. About 4,000 donor hearts are available in the world each year - thousands short of the number required. Yet, transplantation is the only widely practiced long-term treatment for heart patients suffering from end-stage heart failure.
Heart-assist devices, such as WorldHeart's Novacor® LVAS, offer end-state heart patients the opportunity to live more complete, normal, and active lives during Bridge-to-Transplant or Destination Therapy*. This section of the web site is designed to educate and inform you on the topics of Congestive Heart Failure and more.
Note: The information contained within this web site is not intended to substitute for professional advice from doctors or medical practitioners. Rather, it is a resource to improve understanding of heart failure and how it can be treated.
*Currently not FDA approved in the United States. RELIANT Trial (Randomized Evaluation of the Novacor® LVAS In A Non-Transplant Population) is currently underway. Contact Karen Bielinski, Director of Clinical Affairs, at clinical@worldheart.com for more information.
